Skip to content
Clinical Trials – home

Zespol Naukowo-Leczniczy Iwolang Dermatologiczne Centrum Uzdrowiskowe Sp. z o.o.

Research site

Poland Ul. Kulczynskiego 1a, 38-440 Iwonicz-Zdroj, Poland

  • 1 trial recruiting
  • Psoriasis · Dermatitis atopic · Palmoplantar pustulosis
  • Adults and children

About Specializations

Zespol Naukowo-Leczniczy Iwolang Dermatologiczne Centrum Uzdrowiskowe Sp. z o.o. in Iwonicz-Zdroj, Poland specialises in clinical trials of conditions such as Psoriasis, Dermatitis atopic, Palmoplantar pustulosis, and other specialisations. This site conducts important research.

Main research areas of the site

Dermatology and Psoriasis Management

The medical center is at the forefront of dermatology research, with a particular focus on innovative treatments for moderate-to-severe plaque psoriasis. The center's research aims to enhance therapeutic outcomes for patients with specific needs, such as those with a body weight of 120 kg or more.

  • Advanced Psoriasis Treatment Protocols
  • Personalized Medicine in Dermatology
  • Weight-Specific Therapeutic Approaches

Through its research, the center contributes significantly to the development of personalized treatment regimens, optimizing the efficacy of therapies like brodalumab for diverse patient populations.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ul. Kulczynskiego 1a38-440 Iwonicz-ZdrojPoland
Recruiting now
1 trial
Conditions studied
3

More sites in Iwonicz-ZdrojPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

4 clinical trials

Study of Delgocitinib Cream for Adults with Mild to Severe Palmoplantar Pustulosis: A 16-Week Treatment Trial

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Delgocitinib
  • Sponsor:Leo Pharma A/S

Psoriasis

Not recruiting

Study on Long-Term Safety and Efficacy of Deucravacitinib for Patients with Moderate-to-Severe Plaque Psoriasis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Dermatitis atopic

Not recruiting

Study on the Long-term Safety and Effectiveness of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Psoriasis

Not recruiting

Study on Adjustable Brodalumab Dosage for Patients with Moderate-to-Severe Plaque Psoriasis Weighing 120 kg or More

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Brodalumab
  • Sponsor:Leo Pharma A/S
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.